About
COMPANY
Ebvia is a privately held biotechnology company developing a novel, outpatient treatment for breakthrough COVID-19 infections. The drug candidate demonstrated 100% survival against SARS-CoV-2 infection (vs 20% in the control group) in a highly lethal animal model. It also significantly reduced lung and brain pathology in mice infected with the SARS-CoV-2 virus. The candidate is highly potent against the Delta variant and demonstrated strong efficacy against different strains of influenza in animal models.
As we enter the endemic phase of COVID-19, our vision is to provide our communities with a simple to use, safe and effective treatment to address both COVID-19 and influenza.
Leadership
Peter Tam, MBA | President & CEO
Peter Tam serves as President & CEO at Ebvia.
Peter is a pharmaceutical executive with over 25 years of drug development experience. Previously, he served as President and COO of Quadriga Biosciences where he managed the company’s operations, leading the development of the company’s lead compound from IND-enabling studies, CMC manufacturing, IND-filing with the FDA, and the initiation of a first-in-patient study. Prior to Quadriga, Peter served as President and a member of the Board of Directors of VIVUS Inc. Under his leadership, the company successfully developed four drugs from inception and obtained four consecutive NDA approvals. Peter built the company’s R&D pipeline through licensing and acquisition, built and led R&D teams (regulatory, clinical, and CMC), created and developed the company’s patent portfolio, and collaborated with the FDA, corporate partners, and stakeholders to ensure the successful development of the company's products. He helped raise over $500M in corporate financing during his 20-year tenure at VIVUS (1993-2012). He has extensive management experience in drug development, corporate/business development, senior executive leadership, and board experience in the biopharmaceutical industry.
Prior to VIVUS, Peter held various research and clinical development positions at Genentech and XOMA Corporation.
Peter received his BSc in Chemistry from University of California, Berkeley, and his MBA from Leavey School of Business at Santa Clara University. Peter has multiple issued patents and patent applications to his name and serves as a strategic advisor for Quadriga Biosciences.
Eric Tam | COO
Eric Tam serves as COO at Ebvia.
Eric is a life sciences entrepreneur with background in business/corporate development and clinical development, and has held leadership roles at multiple startups. Prior to Ebvia, Eric was Director of Corporate Development at OCTAVE Pharma, where he was responsible for financing activities and in-licensing novel therapeutic and vaccine candidates for Alzheimer’s disease and other neurodegenerative disorders. Eric formerly worked as a clinical project manager on a first-in-class small molecule treatment for glioblastoma at Quadriga Biosciences, a clinical-stage biotechnology company.
Prior to working in the biotechnology industry, Eric worked in investment advisory at Bessemer Trust, a large multifamily office, and as an investor relations intern at ACON Investments, a middle-market private equity firm.
Eric received his bachelor’s from University of California, Irvine and has one patent pending to his name.
Advisors
Bruce Montgomery, M.D. serves as Advisor on Ebvia’s Scientific Advisory Board.
Dr. Montgomery is the CEO of Avalyn Pharma and has 30 years of pharmaceutical company experience in research and drug development. He has raised over $400M in public and private capital and has two exits totaling over $1B. Dr. Montgomery has been instrumental for three complete drug approvals, including aerosolized pentamidine, tobramycin solution for inhalation, and aztreonam lysine for inhalation (the first three FDA approved inhaled antimicrobials); all from invention to advisory board presentations. From 1985 to 1989, Dr Montgomery was co-inventor and led the effort to obtain FDA approval of aerosolized pentamidine, the second AIDS drug approved by the FDA.
While at Genentech between 1989-1993, he started multiple other programs that have led to three other FDA approvals including Pulmozyme, Xolair and Raptiva. In 1998, the Commissioner of the FDA recognized Dr. Montgomery with special citation for leadership in the development and approval of tobramycin solution for inhalation. Dr. Montgomery received a scientific achievement award from the Cystic Fibrosis Foundation for his work on three cystic fibrosis drugs that have extended the average life span by over a decade. In 2011, Dr. Montgomery received a career achievement award from ISAM (International Society for Aerosols in Medicine).
Dr. Montgomery received his BSc in Chemistry in 1975 (magna cum laude, Outstanding Chemistry Major (Merck Award)), and Doctorate of Medicine in 1979 (Alpha Omega Alpha Honor Medical Society) from the University of Washington. Dr. Montgomery is a board-certified internist and pulmonologist. He has authored 26 US patents and over 50 peer-reviewed publications.
Matthew Bogyo, Ph.D. serves as Advisor on Ebvia’s Scientific Advisory Board.
Dr. Bogyo is a Professor of Pathology and Microbiology and Immunology at Stanford University. He is a co-founder of Akrotome Imaging, a small start-up company developing imaging contrast agents for detection of surgical margins, as well as Facile Therapeutics, which is developing novel anti-virulence agents for the treatment of C. difficile infections.
Dr. Bogyo established an independent scientific career as a Faculty Fellow at the University of California, San Francisco, where he supervised a small laboratory of post-doctoral fellows and students. In 2001, Dr. Bogyo was hired to establish and direct the Chemical Proteomics Department at Celera Genomics focused on applying small molecule probes to the field of drug discovery.
Dr. Bogyo then joined the Department of Pathology at Stanford University in July 2003 and was promoted to Associate Professor in 2009, and to full professor in 2013. His laboratory works on the development of new chemical probe technologies that are applied to study the role of proteases in complex biological pathways associated with human diseases. Dr. Bogyo has published over 250 primary research publications and currently serves on the Editorial Board of several prominent research journals. He was the President of the International Proteolysis Society from 2007-2009 and chair of the Gordon Research Conference on Proteolytic Enzymes and Their Inhibitors in 2018 and the Imaging in 2020 meeting in 2016. Dr. Bogyo is also a member of Stanford’s Comprehensive Cancer Center, the Molecular Imaging Program at Stanford (MIPS) and is a consultant for several biotechnology and pharmaceutical companies in the Bay Area. He is the recipient of numerous awards including the Searle Scholar Award, The Terman Fellowship and the Burroughs Wellcome Investigators in Pathogenesis award.
Dr. Bogyo received his BSc in Chemistry from Bates College in 1993 and a PhD in Chemistry from Massachusetts Institute of Technology in 1997.
Robert Booth, Ph.D. serves as Advisor on Ebvia’s Scientific Advisory Board.
Robert is an Adjunct Professor in the School of Medicine at Stanford and has co-founded two spin out companies from Stanford. He also serves on multiple boards and SABs for drug discovery and development companies.
Dr. Booth began his career at Searle, before moving on to Wellcome and then being recruited to Roche. He managed Roche’s R&D organizations in both the US and Europe, and later became Senior Vice President, globally responsible for research and early development in inflammation, autoimmunity, respiratory diseases, bone diseases and virology. He was also a member of the Global Business Development Committee. His team discovered Invirase, the first HIV protease inhibitor to be marketed.
Dr. Booth moved on to become the Chief Scientific Officer at Celera Genomics. There he conceived and initiated the BTK inhibitor program, which discovered Imbruvica. Dr. Booth joined the board of Pharmacyclics that went on to develop Imbruvica, which was launched in 2015 for the treatment of lymphoma. Imbruvica currently has sales of approximately $4B per year.
Dr. Booth received his BSc and PhD from the University of London. He has published more than 50 scientific articles and is an inventor on 10 patents.
Allan Wagman, Ph.D. serves as Advisor on Ebvia’s Scientific Advisory Board.
Dr. Wagman is Executive Vice President, Head of Chemistry and Technical Operations for Rain Therapeutics. He also serves as a chemistry and CMC advisor for Facile Therapeutics. Previously, Dr. Wagman was Head of Chemistry and CMC at 3V Biosciences (now Sagimet Biosciences) bringing novel FASN inhibitor TVB-2640 into clinical Phase 2 studies for treatment of NASH. Before this he was Director of Chemistry for Achaogen Inc., an antibacterial discovery engine which successfully developed and launched aminoglycoside Plazomicin. Dr. Wagman began his pharmaceutical industry career at Chiron Corp., which became a division of Novartis, where he worked on oncology, metabolism and infectious disease programs.
Dr. Wagman received his BSc in Organic Chemistry from Carnegie Mellon University and his PhD in Organic Chemistry from The University of Texas at Austin, and has contributed to over 65 scientific papers and patents.